Andorra Launches Flu and RSV Vaccination Campaigns October 1

Andorra's health authorities will launch the seasonal flu vaccination campaign on October 5, running through January 31, 2027. The programme targets people over 60 and those under 60 with risk factors, who must book appointments at primary care centres. Individuals under 60 with risk factors need to present a prescription from their primary care doctor.

The effort also covers those who may transmit the virus to vulnerable groups, such as staff in healthcare and social health facilities, essential community services workers, and personnel and inmates at the Centre Penitenciari. Procedures will mirror those of prior years.

Last season's campaign, from October 6, 2025, to January 31, 2026, administered 8,091 flu doses—3,809 to men and 4,282 to women. Officials stress the need for yearly shots to counter severe illness, complications, hospital stays, and spread, as flu strains evolve and immunity fades.

A parallel RSV prevention programme starts October 1 and extends to March 31, 2027. It provides nirsevimab to newborns and children under two with risk factors, plus free vaccination for adults over 80 and residents over 60 in social health centres.

Newborns from April 1, 2026, to March 31, 2027, will receive the treatment free at the hospital shortly after birth. The SAAS paediatrics service, in coordination with primary care, will identify other eligible children under two—irrespective of previous doses—notify families, and schedule doses at the day hospital. Infants born abroad who missed it can access it via primary care appointments.

Adults over 80 can get the free RSV vaccine at primary care centres by appointment, with no prescription required. Those over 60 in social health centres will receive it on site. The vaccine is compatible with the flu shot.

Since RSV immunisation started last year, 709 doses have been given, including 626 to people aged 80 and above. The initiative seeks to reduce severe respiratory conditions such as bronchiolitis and pneumonia, lowering hospitalisations and complications among infants, young children, the elderly, and those with chronic illnesses.